ETNB Share Price Performance
US$14.84
7.05 (90.50%)
Price US$14.84
Share Pricen/a
89bio, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
ETNB Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
89bio, Inc. Key Details
About ETNB
- Founded
- 2018
- Employees
- 93
- CEO
- WebsiteView website
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
